Why do these gaps exist, despite 20 years of awareness and guideline campaigns? We and others have described important biological gender differences that contribute to health disparities for women.
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attributes of women and men (both patients and providers) that appear to be contributing to adverse CVD outcome disparities in women.
Similar to prior studies, the VIRGO women were more likely to be diabetic than VIRGO men. Indeed, diabetes is a relatively more potent risk factor for women, with a hazard ratio double that of men (9).
Thus, it makes sense that the VIRGO women were more often diabetic; diabetes is a risk factor with an evidenced-based biological gender difference of rele- Notably, VIRGO women were more often obese than the men. Gender differences in obesity again paradoxically demonstrate that male-pattern visceral obesity is a risk factor (13), whereas general femalepattern obesity is not. Indeed, body weight is not included in any CVD risk prediction score (14) .
General obesity is not an independent risk factor and does not improve CVD risk prediction in women or men. To evidence this sometimes surprising point, CVD mortality has continued to fall despite a robust obesity epidemic in which 74% of men and 64% of women are now overweight/obese (15), and obesity reduction trials have failed to reduce CVD (16) .
So if obesity is not a risk factor or treatment target for CVD, why were the women in VIRGO more obese than the men? A cultural gender bias is again likely.
Sexism is defined as attitudes or behavior based on traditional stereotypes of gender roles, including the sexual objectification of women (17) . Prior study demonstrates that women are relatively more "objectified" in society, that is, judged by their appearance and physical attributes, than men, and indeed, women themselves reflect this gendered societal stance by expressing more concern about their bodyweight than men (18 New national survey data from the Women's Heart
Alliance support the concept that this misogyny impacts preventive heart care. Our nationally representative survey demonstrates that women report they are most often advised by health care providers that they are overweight/obese rather than assessed for validated risk factors when discussing heart disease risk (20) . Further survey results indicate that women absorb this misogynistic messaging and report deferring visits to health care providers "until they have lost some weight" (20) . These data indicate that heart health risk assessment and preventive therapy are stigmatized by gendered issues of physical appearance for women.
What must be done to close gender guideline gaps that contribute to the adverse CVD mortality in our young women? The Women's Heart Alliance (21) has launched a nationwide campaign of: 1) awareness to destigmatize heart disease among women and providers (FighttheLadyKiller); 2) action to empower women to request and providers to use the ASCVD heart risk check (#getheartchecked); and 3) advocacy to increase heart disease research in women (22), who now constitute the majority of victims yet remain a minority of research subjects (23) . Providers should test themselves regarding gender, obesity, ethnicity, and other biases using the short and free "Implicit Bias" test (24). Prior work demonstrates that those who firmly believe that they are unbiased test out as the most biased (25) . The misogyny of obesity is a gendered social stigma that contributes to women not discussing heart health and providers failing to use evidencebased assessment and therapy. Communication and outreach are sorely needed to counter stereotypes about heart disease with facts and validated risk assessment so women and physicians can know and practice the truth.
